São Paulo to Launch Statewide Dengue Vaccination With Butantan Single‑Dose Shot on Feb. 9

Overview

• The campaign begins Monday across all 645 municipalities, with the first phase limited to municipal primary‑care professionals.
• The National Immunization Program sent 99,000 doses for the launch, and the state estimates about 216,000 workers will be immunized.
• Butantan‑DV, developed by Instituto Butantan, is a single‑dose tetravalent vaccine approved by Anvisa for people aged 12 to 59.
• Phase 3 results indicate roughly 75% efficacy against overall dengue, over 91% against severe disease, and 100% protection against hospitalizations, with mostly mild adverse reactions reported.
• State and federal health authorities organized distribution and technical monitoring, citing a heavy recent dengue burden in São Paulo, including 4,647 cases and one death reported in 2026 through Feb. 5.